MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma

Imagem de Miniatura
Arquivos
art_FERNANDES_MAP_Kinase_Pathways_Molecular_Roads_to_Primary_Acral_2015.PDF (400.48 KB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2015
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
FERNANDES, Juliana D.
HSIEH, Ricardo
FREITAS, Luiz A. R. de
BRANDAO, Miguel A. R.
SANGUEZA, Martin
Citação
AMERICAN JOURNAL OF DERMATOPATHOLOGY, v.37, n.12, p.892-897, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The etiology and pathogenesis of lentiginous acral melanomas are poorly understood. Recent studies have postulated that DNA repair mechanisms and cell growth pathways are involved in the development of melanoma, particularly changes in the MAPK pathways (RAS, BRAF, MEK 1/2, and ERK 1/2). The aim of this study is to assess the status of the MAP kinase pathways in the pathogenesis of acral melanomas. The authors examined the components of the RAS-RAF-MEK-ERK cascades by immunohistochemistry in a series of 16 primary acral melanomas by tissue microarray. The expression of MAP kinase cascade proteins changed in most cases. The authors observed that 57.14% of cases were BRAF positive and that 61.53%, 71.42%, and 71.42% of cases were positive for MEK2, ERK1, and ERK2, respectively; RAS was not expressed in 92.31%, and all cases were negative for MEK1. The absence of RAS and positivity for MEK2, ERK1, and ERK2 were most seen in invasive cases with high thickness. These aspects of the MAPK pathway require further examination in acral melanomas between different populations. Nevertheless, the results highlight significant alterations in the MAP kinase cascades that are related to histological indicators of prognosis in primary acral melanomas.
Palavras-chave
melanoma, acral, skin cancer
URI
https://observatorio.fm.usp.br/handle/OPI/13909
Referências
  1. Bartkova J, 1996, CANCER RES, V56, P5475
  2. Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026
  3. Weber A, 2003, LAB INVEST, V83, P1771, DOI 10.1097/01.LAB.0000101732.89463.29
  4. Spugnardi M, 2003, CANCER RES, V63, P1639
  5. Piliang MP, 2011, CLIN LAB MED, V31, P281, DOI 10.1016/j.cll.2011.03.005
  6. Venesio T, 2008, MODERN PATHOL, V21, P716, DOI 10.1038/modpathol.2008.41
  7. Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446
  8. Scholl FA, 2009, CANCER RES, V69, P3772, DOI 10.1158/0008-5472.CAN-08-1963
  9. Sasaki Y, 2004, J INVEST DERMATOL, V123, P177, DOI 10.1111/j.0022-202X.2004.22722.x
  10. Reifenberger J, 2004, INT J CANCER, V109, P377, DOI 10.1002/ijc.11722
  11. Kuchelmeister C, 2000, BRIT J DERMATOL, V143, P275, DOI 10.1046/j.1365-2133.2000.03651.x
  12. Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106
  13. Edlundh-Rose E, 2006, MELANOMA RES, V16, P471, DOI 10.1097/01.cmr.0000232300.22032.86
  14. Takata M, 2005, J INVEST DERMATOL, V125, P318, DOI 10.1111/j.0022-202X.2005.23812.x
  15. O'Leary JA, 2000, CLIN ORTHOP RELAT R, P206
  16. Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861
  17. Zebary A, 2013, J DERMATOL SCI, V72, P284, DOI 10.1016/j.jdermsci.2013.07.013
  18. Bello DM, 2013, ANN SURG ONCOL, V20, P3618, DOI 10.1245/s10434-013-3089-0
  19. Hsieh R, 2013, AM J DERMATOPATH, V35, P167, DOI 10.1097/DAD.0b013e31825fa1f6
  20. vanElsas A, 1996, AM J PATHOL, V149, P883
  21. Buery RR, 2011, ONCOL REP, V26, P783, DOI 10.3892/or.2011.1385
  22. Kong YY, 2010, ARCH PATHOL LAB MED, V134, P1740, DOI 10.1043/2009-0418-RAR.1
  23. Hong JW, 2014, ANN DERMATOL, V26, P195, DOI 10.5021/ad.2014.26.2.195
  24. Uribe P, 2006, J INVEST DERMATOL, V126, P161, DOI 10.1038/sj.jid.5700011
  25. Markovic SN, 2007, MAYO CLIN PROC, V82, P364
  26. Satyamoorthy K, 2003, CANCER RES, V63, P756
  27. Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092
  28. Greaves WO, 2013, J MOL DIAGN, V15, P220, DOI 10.1016/j.jmoldx.2012.10.002
  29. Jiveskog S, 1998, J INVEST DERMATOL, V111, P757, DOI 10.1046/j.1523-1747.1998.00376.x
  30. Tan KB, 2007, AM J SURG PATHOL, V31, P1902, DOI 10.1097/PAS.0b013e318073c600
  31. Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152
  32. Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669
  33. Bradford PT, 2009, ARCH DERMATOL, V145, P427, DOI 10.1001/archdermatol.2008.609
  34. Bristow IR, 2008, J FOOT ANKLE RES, V1, DOI 10.1186/1757-1146-1-11
  35. SLINGLUFF CL, 1990, J SURG ONCOL, V45, P91, DOI 10.1002/jso.2930450207
  36. Bastian BC, 2000, CANCER RES, V60, P1968
  37. Jovanovic B, 2008, J INVEST DERMATOL, V128, P2696, DOI 10.1038/jid.2008.134
  38. Pollack LA, 2011, J AM ACAD DERMATOL, V65, pS78, DOI 10.1016/j.jaad.2011.05.030
  39. Jarell Abel D, 2007, Biologics, V1, P407
  40. Palmieri G, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-86
  41. Reed R., 1976, NEW CONCEPTS SURG PA
  42. Richmond-Sinclair NM, 2008, MELANOMA RES, V18, P336, DOI 10.1097/CMR.0b013e32830d8329
  43. Wu XC, 2011, J AM ACAD DERMATOL, V65, pS26, DOI 10.1016/j.jaad.2011.05.034

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/06
Artigos e Materiais de Revistas Científicas - ODS/03